Multi-cancer early detection Market Outlook 2026–2036: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines multi-cancer early detection, blood tests that look for fragments of tumour DNA and other signals to detect several cancers at once, many of which have no recommended screening test. It tests how fast these tests move from laboratory services into approved, covered screening, and which participants capture value among test developers, laboratories, sequencing suppliers, health systems and payers.

The regulatory path has opened. GRAIL announced in January 2026 that it had submitted the final module of a premarket approval application to the US Food and Drug Administration for the Galleri test, supported by the PATHFINDER 2 study of 25,490 participants with one year of follow-up and the first screening round of the NHS-Galleri trial of more than 140,000 adults aged 50 to 77. The company expects an FDA advisory committee review in the fall of 2026. The conclusion is that a first decision on a multi-cancer test for population screening is close, and its outcome sets the rules for every other developer.

The trial evidence is positive on detection and mixed on stage shift. At the ASCO meeting in May 2026, NHS-Galleri did not significantly reduce combined stage III and IV cancers, while stage IV diagnoses of 12 prespecified aggressive cancers fell 22% in the second round and 26% in the third. PATHFINDER 2 found that about 60% of cancers detected were found by screening when Galleri was added to recommended screenings, 53% of newly detected cancers were stage I or II, and the cancer signal origin was identified correctly more than 90% of the time. The conclusion is that the tests detect many cancers that are otherwise missed, and the case for a mortality benefit still rests on later trial results.

Commercial demand is already visible. GRAIL reported second quarter 2026 Galleri revenue of USD 42.6 million, up 24%, with more than 61,000 tests, up 35%, and cash of USD 861.6 million, against a net loss of USD 110.2 million. The conclusion is that laboratory sold tests are growing at a steady pace without approval, and the company must reach approval and coverage before the balance sheet limits its plans.

The brief treats multi-cancer early detection as a high-impact signal with a ten year horizon to 2036. It identifies which applications, regions and operators scale first and what each means for test developers, laboratories, sequencing suppliers, health systems and payers. It is a focused 106-page decision brief that presents an indicative trajectory rather than a segmented market model.

Multi-cancer early detection tests analyse a blood sample for tumour derived signals, mainly fragments of cell free DNA, to detect the presence of cancer and predict the organ where it started.

The leading method reads methylation patterns of cell free DNA by sequencing and applies machine learning to a signal and its origin. Other methods use DNA fragment patterns, protein markers or a combination of analytes.

A positive result leads to diagnostic imaging and tests to confirm the cancer, so the tests act as an added step ahead of the diagnostic pathway and complement recommended screening.

Uses are screening of adults aged 50 and older, screening of higher risk groups and detection of cancers that have no recommended screening, each under laboratory test or device rules.

The limits are lower sensitivity for early stage cancers, false positives and the cost of work up, absence of a demonstrated mortality benefit, and limited coverage. The period turns on whether approval and trial results lead to guideline inclusion and payment.

The multi-cancer early detection market, covering blood based tests that screen for several cancers at once, including laboratory services, sequencing consumables and related analysis software, is valued at USD 0.3–0.5 billion in 2026 and is projected to reach USD 6.03–10.05 billion by 2036, at a CAGR of 35%.

The 2026 base rests on laboratory services, sequencing consumables and software for blood based multi-cancer tests, sold through physicians, health plans and employers. Growth then follows an FDA decision, trial results, coverage and falling sequencing cost.

The forecast is sensitive to the FDA decision, evidence of mortality benefit and coverage by payers. Regionally, North America leads on commercial sales and regulatory review, Europe on the NHS trial and decisions, and Asia-Pacific on partnerships in South Korea, Japan and Singapore.

Base case.

The base case assumes the first FDA decision allows marketing for adults at elevated risk and further trials support coverage by 2031, giving the inflection in 2031.

Accelerated case.

An accelerated case assumes broad approval, mortality evidence and early guideline inclusion, bringing the inflection to 2029 and lifting the 2036 value to the top of the range.

Delayed case.

A delayed case assumes a restricted or deferred decision and limited coverage, holding growth at the bottom of the range.

Growth drivers

• Cancers with no recommended screening test.
• Trial evidence on detection.
• Employer and health plan coverage.
• Falling sequencing cost.

Enablers

• Regulatory pathways and Breakthrough designation.
• Health system and payer partnerships.
• Machine learning and large cohorts.
• Laboratory capacity.

Restraints and barriers

• No demonstrated mortality benefit.
• False positives and diagnostic work up burden.
• Limited coverage and test price.
• Lower sensitivity for early stage cancers.

The direction of multi-cancer early detection is set by the need to detect cancers that have no screening test, regulation and coverage, new assays and machine learning, partnering among health systems, payers and developers, and sequencing cost and test price.

The key participants in multi-cancer early detection include GRAIL, Inc., Exact Sciences Corporation, Guardant Health, Inc., Illumina, Inc., Natera, Inc., Freenome Holdings, Inc., Delfi Diagnostics, Inc., Harbinger Health Inc., Singlera Genomics Inc., Burning Rock Biotech Limited, BGI Genomics Co., Ltd., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, F. Hoffmann-La Roche Ltd, Samsung Electronics Co., Ltd., Tempus AI, Inc., Caris Life Sciences, Inc., Personalis, Inc., Thermo Fisher Scientific Inc., Veracyte, Inc., NHS England, Cancer Research UK, National Cancer Institute, American Cancer Society, Mayo Clinic, MD Anderson Cancer Center, Cleveland Clinic, UnitedHealth Group Incorporated, Priority Health, American Society of Clinical Oncology, National Comprehensive Cancer Network, U.S. Preventive Services Task Force, U.S. Food and Drug Administration, Centers for Medicare & Medicaid Services, Medicines and Healthcare products Regulatory Agency, National Medical Products Administration, Pharmaceuticals and Medical Devices Agency, European Commission, Clinical and Laboratory Standards Institute and College of American Pathologists.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as multi-cancer early detection matures.

GRAIL leads with the first premarket application and the largest trials, Exact Sciences, Guardant Health, Freenome, Delfi Diagnostics and Harbinger Health compete with their own tests, and Illumina, Roche and Thermo Fisher Scientific supply sequencing and diagnostics. Laboratory Corporation of America Holdings and Quest Diagnostics hold the clinical laboratory channel, and Samsung Electronics is the partner for South Korea. Competitive intensity is high in 2026 and rises as the first decision approaches.

Where value migrates.

In 2026 value sits with developers that have trial evidence and laboratory volume, because early buyers are physicians, employers and plans that pay for a detected cancer. By 2031 it moves toward companies with approved tests and coverage, because payers reimburse only what regulators and guidelines accept. By 2036 it settles in integrated platforms that join screening, diagnostic work up and data. Margins hold for developers with approval, scale and low cost sequencing and narrow for tests sold without coverage.

The signals converge on regulatory progress and commercial volume. A first application was filed in January 2026, trials of more than 140,000 and 25,490 participants have reported, and more than 61,000 tests were sold in one quarter. Each signal supports growth, and the lack of a demonstrated mortality benefit, false positives and coverage limit the pace.

Structural limits show where progress could slow: absence of a demonstrated mortality benefit, the burden of diagnostic work up after a positive result, limited coverage and test price, and lower sensitivity for early stage cancers. The brief therefore tracks four indicators: regulatory decisions, trial readouts, coverage decisions, and tests performed.

Higher risk adults and cancers without screening first, then adults aged 50 and older alongside recommended screening, then wider population screening are the expected order of adoption.